Topics

Pirfenidone and Advanced Liver Fibrosis.

2019-09-26 05:42:32 | BioPortfolio

Summary

Pirfenidone (PFD), an oral antifibrotic drug with anti-inflammatory and anti-oxidant properties, has been granted marketing authorization by the European Medicine Agency and FDA, for the treatment of idiopathic pulmonary fibrosis (IPF). However, few studies have focused on its clinical utilization in patients with advanced hepatic fibrosis. Therefore, Investigators aim to evaluate a prolonged-release PFD formulation (PR-PFD) plus standard of care management on disease progression in patients with advanced liver fibrosis (ALF).

Methods: Patients with diverse chronic liver disease etiology (alcohol-related, hepatitis B or C, autoimmune or fatty liver disease) will be screened with two non invasive liver fibrosis methods (Fibroscan®) and Fibro Test®) and those with ALF (F3 or F4) will be treated for at least 12 months with PR-PFD. Antifibrotic effects Will be assessed at 6 and 12 months; variations greater than 30% in estimated fibrosis scores or 1 point on the METAVIR scale will be considered clinically significant. PFD plasma levels, serum endothelin-1, IL6, TNFα and TGFβ1, Quality of life and fatigue scales will be evaluated. Parametric and non parametric statistics will be utilized and p values lower tan 5% will be considered clinically significant.

Description

The study will be conducted in compliance with International Standard good clinical practices (GCPs) and the Declaration of Helsinki. The protocol was approved by local Institutional Review Board and registered in clinical trials.gov.

Clinical and Laboratory Evaluation Blood counts and liver function tests (bilirubin, albumin, prothrombin time expressed as international normalized ratio (INR), serum transaminases, glucose, and creatinine) are measured at 12-week intervals. Patient's somatometric measurements (height and body weight), vital signs, and frequency of adverse events (AE) are recorded. Liver enzymes will be scored as stable, improving, or worsening.

Study End Points The primary efficacy endpoint is a reduction of fibrosis score by at least 30% either in Fibro Test units or kilo Pascals (kPa) according to hepatic elastography or a reduction of 1 point on the METAVIR scale. Secondary efficacy endpoints include improvement in alanine aminotranferase (ALT) and/or aspartate aminotransferase (AST), albumin, serum concentrations of TGFbeta, IL-1 and IL-6 and endothelin, and Child-Pugh and MELD scores. Worsening MELD is defined as switching from a lower-score to a higher-score and improving as switching from a higher-score to a lower-score, where Group 1 was MELD ≤ 9, Group 2 10-19, and Group 3 > 20.

Primary safety endpoints include clinical side effects, blood profile abnormalities, overall survival, and pharmacokinetic (PK) findings. Secondary safety endpoints included quality of life scores.

Evaluation and Classification of Fibrosis Outcomes Fibrosis-regression profile (FRP): decreases >30% in FT score or 30% in kPa in liver stiffness measurement (LSM) or decreasing 1 point on the METAVIR score comparing baseline and M12 measurements.

Fibrosis-stabilization profile (FSP): stable FT results or kPa measurements (variations lower than 30%) or METAVIR score.

Fibrosis-progression profile (FPP): increases greater than 30% in FT score or kPa or increasing 1 point on METAVIR.

Specific Evaluation and Classification of Biochemical Outcomes Biochemical markers: Blood parameters determined after overnight fasting include: albumin, prothrombin time, total bilirubin, ALT, AST, Alkaline phosphatase (AP), and gamma-glutamyltransferase (GGT), measured in fresh serum within 8h of collection on an automated biochemistry analyzer (Hitachi 917; Roche Diagnostics).

alpha-2-macroglobulin (A2M), apolipoprotein-A1, and haptoglobin levels will be assayed by nephelometry (Image; Beckman Coulter).

Fibro Test®: blinded Fibrotest measurements will be performed on fresh serum and according to the recommended pre-analytic and analytic methods.

Hepatic elastography: Transient Elastography (TE) is performed according to published recommendations using the Fibro-Scan® M probe. LSM is expressed in kPa. Only procedures with at least 10 validated measurements, >60% success rate, and an interquartile range <30% of the median will be considered reliable. Patients with ascites will be offered real time shear wave elastography (Aixplorer, Supersonic Imagine).

Cytokines and pirfenidone: Serum concentrations of Interleukin 6 (IL-6), transforming growth factor beta (TGF-β1), endothelin 1 (ET-1), and tumor necrosis factor alpha (TNF-α) will be quantified by ELISA in an automated enzyme-linked immunosorbent assay (EIA) analyzer Coda Microplate System (Bio-Rad Laboratories, Inc., Hercules, California, USA) and values normalized against serum of healthy volunteers with normal liver function and LSM <5 kPa (F0).

Evaluation of Safety Profile Monitoring for safety and toxicity will be performed throughout the study. When necessary, appropriate medical intervention will be provided.

Quality of life assessment: All patients will fill out the Euro-Qol Index survey, including the visual analog scale evaluation at baseline and at 12 months. Investigators incorporate the nonutility-based Short Form-36v2 survey, which provides a detailed profile of health-related quality of life.

Ethical considerations. The study will be conducted in accordance with the Declaration of Helsinki and the E6 Good Clinical Practice Standards International Conference on Harmonization (ICH).

Statistical Data Analysis: Investigators will be using the Statistical Package for the Social Sciences (SPSS) Statistical software 6.12 for Windows. Descriptive statistics include mean, standard deviation standard error. A paired or unpaired t Test will be used to compare means before and after study medication administration. Values <5% will be considered significant. Kaplan Meier survival analyses will include all patients on active study-medication treatment despite duration of exposure. Sample size calculation was based on the following assumptions: (1) mean expected baseline elastography score of 27.4 kPa, standard deviation of 15.7; expected estimated-fibrosis reduction rate higher than 30% (delta); (4) alpha error of 1%; (5) an accepted beta error of 10% (power = 90%); (6) two tails. The final number of patients required to find a significant difference using the G power statistical program was 61 patients.

Study Design

Conditions

Liver Fibrosis

Intervention

Pirfenidone, Standard of care

Location

Liver Clinic 1
Mexico City
Mexico

Status

Recruiting

Source

Grupo Mexicano para el Estudios de las Enfermedades Hepaticas

Results (where available)

View Results

Links

Published on BioPortfolio: 2019-09-26T05:42:32-0400

Clinical Trials [3832 Associated Clinical Trials listed on BioPortfolio]

Pirfenidone in Treating Patients With Fibrosis Caused by Radiation Therapy for Cancer

RATIONALE: Pirfenidone may prevent or lessen fibrosis caused by radiation therapy. PURPOSE: Pilot trial to study the effectiveness of pirfenidone in preventing or lessening fibrosis in pa...

Pirfenidone for the Treatment of Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis (PF/IPF)

To assess the long-term safety and efficacy of oral pirfenidone in doses of up to 40 mg/kg/d in a limited number of patients with pulmonary fibrosis/idiopathic pulmonary fibrosis (PF/IPF)

Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis

The objectives of this study are to assess the safety and efficacy of treatment with pirfenidone 2403 mg/d compared with placebo in patients with idiopathic pulmonary fibrosis (IPF), to as...

A Clinical Study to Test How Effective and Safe GLPG1205 is for Patients With Idiopathic Pulmonary Fibrosis (IPF)

This is a randomized, double-blind, parallel group, placebo-controlled, multicenter, exploratory Phase II study including subjects with Idiopathic Pulmonary Fibrosis (IPF), investigating G...

A Safety and Tolerability Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis

This is a single arm, multicenter, open-label, Phase 1b study to evaluate the safety and tolerability of vismodegib in combination with pirfenidone in participants with idiopathic pulmonar...

PubMed Articles [19102 Associated PubMed Articles listed on BioPortfolio]

Pirfenidone alleviates concanavalin A-induced liver fibrosis in mice.

Liver fibrosis (LF) is a life-threatening complication of most chronic liver diseases resulting from a variety of injurious agents and hepatotoxic insults. To date, there are no specific therapies for...

Acute liver failure during Pirfenidone treatment triggered by co-medication with Esomeprazole.

Prifenidone is an antifibrotic agent for the treatment of Idiopathic Pulmonary Fibrosis (IPF) that improves the outcome of patients and is recommended by guidelines [1]. In few patients however, Pirfe...

Liver Ultrasound Patterns in Children with Cystic Fibrosis Correlate with Non-Invasive Tests of Liver Disease.

Early identification of children with cystic fibrosis (CF) at risk for severe liver disease (CFLD) would enable targeted study of preventative therapies. There is no gold standard test for CFLD. Ultra...

Pirfenidone in real life: A retrospective observational multicentre study in Italian patients with idiopathic pulmonary fibrosis.

Real-world data on pirfenidone treatment of patients with idiopathic pulmonary fibrosis (IPF) are limited. This study assessed the effectiveness of pirfenidone in a large real-life Italian IPF cohort.

Renoprotective effects of pirfenidone on chronic renal allograft dysfunction by reducing renal interstitial fibrosis in a rat model.

Pirfenidone (PFD) has been used as medication for idiopathic pulmonary fibrosis due to its ability in reducing lung fibrosis. However, the underlying mode of action in renal fibrosis during chronic re...

Medical and Biotech [MESH] Definitions

The minimum acceptable patient care, based on statutes, court decisions, policies, or professional guidelines.

FIBROSIS of the hepatic parenchyma due to chronic excess ALCOHOL DRINKING.

Organization of medical and nursing care according to the degree of illness and care requirements in the hospital. The elements are intensive care, intermediate care, self-care, long-term care, and organized home care.

Irreversible FIBROSIS of the submucosal tissue of the MOUTH.

An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.

More From BioPortfolio on "Pirfenidone and Advanced Liver Fibrosis."

Quick Search

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...


Searches Linking to this Trial